Drug shortage
Parathyroid Hormone Injection · Takeda Pharmaceuticals USA Inc.
FDA drug shortage · Current · updated Apr 15, 2025
Key facts
| Generic name | Parathyroid Hormone Injection |
|---|---|
| Proprietary name | Natpara |
| Company | Takeda Pharmaceuticals USA Inc. |
| Presentation | Natpara, Injection, 100 ug/.08 mL, Injection, Powder, Lyophilized, For Solution (NDC 68875-0205-2) |
| Dosage form | Injection |
| Strength | 100 ug/.08 mL, Injection, Powder, Lyophilized, For Solution |
| Status | Current |
| Reason for shortage | Discontinuation of the manufacture of the drug |
| Therapeutic category | Endocrinology/Metabolism |
| Package NDCs | 68875-0205-2 |
| First posted | Sep 11, 2019 |
| Last updated | Apr 15, 2025 |
At a glance
- 1–9 Package NDCs affected
- 1–9 FDA shortage records for this drug
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About FDA drug shortages
The FDA Drug Shortages Database lists current and resolved shortages of drugs, with presentations, affected NDCs and reasons reported by manufacturers.
Source: U.S. Food and Drug Administration (FDA), Drug Shortages Database · Source date: